Predictive
Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company,
applies its smart tumor profiling and artificial intelligence (“AI”) platform
to extensive genomic and biomarker patient data sets to predict and improve
clinical outcomes for cancer patients. An article discussing the company reads,
“While precision medicine, sometimes referred to as personalized medicine, is a
relatively new term, the idea has been around for years (http://ibn.fm/KlNJH). Defined by
the U.S. National Library of Medicine as ‘an emerging approach for disease
treatment and prevention that takes into account individual variability in
genes, environment, and lifestyle for each person,’ the approach is gaining
momentum as data sets especially in genomics have grown rapidly. Applying AI
approaches to these large data sets offers the ability to more deeply analyze
these data much faster and with more accurate results than previously. . .
.Predictive Oncology is at the forefront of this growing trend that examines
multiple factors about the patient from genomics, tumor profiles, nutrition,
environmental factors, lifestyle and habits to determine a plan of action for
treatment. In a recent overview (http://ibn.fm/pYVQI),
POAI notes that for years, big pharma has invested tremendous resources — both
financial and human — in genomics in order to understand a patient’s genome and
hopefully provide more targeted treatments. However, despite the significant
amount of time and money devoted to the research, success rates for such
targeted therapies remain low, and adoption in clinical practice is lukewarm.
It has become increasingly clear that genomics alone is not enough. . . . Enter
Predictive Oncology. Competitors in the cancer field must wait at least five
years to determine patient survival rates for specific treatments before they
can show value in the data they have gathered. POAI, on the other hand, has
vast amounts of historical data that it has been compiling for years,
time-tested and proven data that can be leveraged today.”
To view the full article, visit http://ibn.fm/ZYttK
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on
applying artificial intelligence to personalized medicine and drug discovery.
The company applies smart tumor profiling and its AI platform to extensive
genomic and biomarker patient data sets to predict clinical outcomes and, most
importantly, improve patient outcomes for cancer patients of today and
tomorrow. Predictive Oncology currently has approximately 150,000 clinically
validated cases on its molecular information platform, with more than 38,000
specific to ovarian cancer. The company’s data is highly differentiated, having
both drug-response data and access to historical outcome data from patients.
Predictive Oncology intends to generate additional sequence data from these
tumor samples to deliver on the clear, unmet market need across the
pharmaceutical industry for a multi-omic approach to new-drug development. For
more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
